ALNY Q2 2020 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$104M+132.5% YoY

Gross Profit

$84M80.8% margin

Operating Income

-$199M-191.3% margin

Net Income

-$179M-172.4% margin

EPS (Diluted)

$-1.56

QoQ Revenue Growth

+4.5%

Cash Flow

Operating Cash Flow

-$135M

Free Cash Flow

-$152M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$2.0B

Stockholders' Equity

$1.4B

Cash & Equivalents

$581M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$104M	$45M	+132.5%
Gross Profit	$84M	$40M	+108.1%
Operating Income	-$199M	-$236M	+15.8%
Net Income	-$179M	-$219M	+18.3%

Revenue Segments

Product

$78M50%

ONPATTRO

$67M43%

GIVLAARI

$11M7%

Geographic Segments

UNITED STATES

$41M53%

Europe

$25M33%

Non-US Or Europe

$11M15%